IT
-
EN
Home
About Us
Our Mission
History
Corporate Structure
Key Financial data
Key Data
Net Sales
Sales by Business
Pharmaceuticals: Net Sales
Key P&L and EBITDA
Balance Sheet Structure
Per Share Data
Management
Contacts
Pharmaceutical Operations
Markets
Specialty and Primary Care
Rare Diseases
Products
Specialty and Primary Care Products
Rare Diseases Products
R & D
Pipeline
Pubblications
Pharmaceutical Production
Pharmaceutical Chemicals
Products
Production
D.M.F. & C.E.P.
Rare Diseases
Investors
Recordati at a glance
Recordati Share
Key Financial data
Key data
Net Sales
Sales by Business
Pharmaceuticals: Net Sales
Key P&L and EBITDA
Balance Sheet Structure
Per Share Data
News & Announcements
Business & financial news
Other press releases
Announcements
Public Tender Offer
Company Presentations
Annual & Interim Reports
Regulated Information Service Providers
Shareholders' Meetings
Reverse Merger into Recordati S.p.A. 2020/2021
Regulations for Shareholders' Meetings
Calendar
Analyst Coverage
Contacts IR
Internal Dealing
Internal Dealing Regulations
Internal Dealing Press Releases
Sustainability
Sustainability strategy
Group’s Stakeholders
Materiality Analysis
Sustainability Plan
Sustainability governance
Business ethics & integrity
The Organisational, Management and Control Model
Internal Audit and Risk Management System
People's health: Recordati's priority since the beginning
Research & Development
Access to medicine and healthcare
Product quality and safety
Responsible marketing
The Recordati group’s employees
The importance of our employees
Diversity and equal opportunities
Remuneration and benefit system
Training and development of human capital
Health and safety
Industrial relations
Focus on the environment
Commitment to environmental protection
Energy use
Principal initiatives to combat climate change
Water management
Waste management
Suppliers and strategic partners
Supply-chain profile and responsible sourcing
Support for local communities
Donations
Initiatives in the context of the COVID-19 emergency
Documents
Contact
Corporate Governance
Company by Laws
Board of Directors
Board of Statutory Auditors
Firm of Auditors
Shareholders agreements
In force
Historical Record
Report on Corporate Governance and the Ownership Structure
Remuneration
Remuneration Reports
Stock Option Plans
Share Buy-back
Related Parties
Regulations for Related-Party Transactions
Compliance programmes
Changes in share capital
Other Corporate Documents
Corporate Affairs Contacts
Relevant Information and Inside Information
News & Announcements
Business & financial news
Other press releases
Announcements
Partnering
Our Capabilities
Our Needs
Contacts
Selected Partnerships
Join Us
Training for further development
Internships: start building Your future
Professional Areas
International Presence
Recordati offers a wide range of innovative medicines, mainly for cardiovascular and urological disorders, and unique treatments for rare diseases.
Dedicated to treating the most vulnerable.
Recordati Rare Diseases, the Recordati company dedicated to treatments for rare diseases.
We are also present in the self-medication segment and have always been committed to the improvement of quality of life by offering successful products with well-known brands.
New products, new clinical trials, new projects in new therapeutic areas: these are Recordati’s commitments and are a fundamental premise for its growth.
Last News
RECORDATI: FIRST HALF OF 2021 RESULTS APPROVED, REVENUE +1.4%, EBITDA -3.4%, NET INCOME +5.2%. RETURN TO GROWTH IN THE SECOND QUARTER
Business & financial news
About
Us
Recordati is a respected international pharmaceutical group and partner of important companies. >>
Rare
Diseases
Each person with a rare disease has the right to the best treatment. >>
Research
&
Development
With an eye on the future the Recordati group invests significantly in research and development. >>
International
Presence
Towards a global presence, a strategy of international development. >>
Partnering
Committed to generating future value by enacting an intelligent partnering policy. >>
Share Price
- Investors
“The most valuable currency in financial markets is reliable information”.
(Michael Bloomberg, Mary Shapiro)
>>
Annual Report
Corporate Brochure
The Prize
Alert Service